457 related articles for article (PubMed ID: 30413667)
21. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
22. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
Smith J; Irwin A; Jensen L; Tedesco K; Misir S; Zhu W; Almonte A; He Y; Xie R; Olivo M; O'Shaughnessy J
Clin Breast Cancer; 2020 Apr; 20(2):160-167. PubMed ID: 31980406
[TBL] [Abstract][Full Text] [Related]
23. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
24. Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.
Quaquarini E; Sottotetti F; D'Ambrosio D; Malovini A; Morganti S; Marinello A; Pavesi L; Frascaroli M
Future Oncol; 2017 Apr; 13(11s):11-23. PubMed ID: 28481185
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
[TBL] [Abstract][Full Text] [Related]
26. Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life.
De Luca R; Alù M; Genova G; Grassadonia A; Cicero G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12727-12734. PubMed ID: 33378020
[TBL] [Abstract][Full Text] [Related]
27. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
Aseyev O; Ribeiro JM; Cardoso F
Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
[TBL] [Abstract][Full Text] [Related]
28. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
29. Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.
La Verde N; Piva S; Ganzinelli M; Farina G; Gherardi G; Girelli S; Bramati A; Del Re L; Damia G
Future Oncol; 2013 Nov; 9(11):1703-9. PubMed ID: 24156329
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.
Goodin S; Barbour S; Song J; Berrak E; Cox D
Am J Health Syst Pharm; 2015 Dec; 72(24):2150-6. PubMed ID: 26637514
[TBL] [Abstract][Full Text] [Related]
31. Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S; Nakayama T; Yoshinami T; Watanabe KI; Hara F; Sagara Y; Kawaguchi H; Higaki K; Matsunami N; Hasegawa Y; Takahashi M; Mizutani M; Morimoto T; Sato M; Itoh M; Morita S; Masuda N
Breast Cancer; 2018 Jul; 25(4):438-446. PubMed ID: 29435730
[TBL] [Abstract][Full Text] [Related]
32. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
[No Abstract] [Full Text] [Related]
34. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Hardy-Bessard AC; Brocard F; Clatot F; Lortholary A; You B; Grenier J; Martin-Babau J; Lucas B; Meunier J; Ferrero JM; Savoye AM; Marti A; Despax R; Moullet I; Emile G
Breast; 2020 Dec; 54():256-263. PubMed ID: 33188992
[TBL] [Abstract][Full Text] [Related]
35. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
[TBL] [Abstract][Full Text] [Related]
36. Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
Kobayashi T; Tomomatsu J; Fukada I; Shibayama T; Teruya N; Ito Y; Iwase T; Ohno S; Takahashi S
BMC Cancer; 2016 Jul; 16():404. PubMed ID: 27389013
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
Tanaka T; Ueno M; Nakashima Y; Chinen S; Sato E; Masaki M; Mogi A; Sasaki H; Tamura K; Takamatsu Y
Thorac Cancer; 2017 Sep; 8(5):523-529. PubMed ID: 28741868
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Barni S; Livraghi L; Gravina A; Martella F; D'Onofrio L; Morritti M; Michelotti A; Vici P; Mentuccia L; Porcu L; Orditura M; Puglisi F;
J Geriatr Oncol; 2019 Nov; 10(6):990-993. PubMed ID: 31097340
[No Abstract] [Full Text] [Related]
39. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.
Mougalian SS; Feinberg BA; Wang E; Alexis K; Chatterjee D; Knoth RL; Nero D; Miller T; Liassou D; Kish JK
Future Oncol; 2019 Dec; 15(34):3935-3944. PubMed ID: 31660764
[No Abstract] [Full Text] [Related]
40. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
